|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-8-21 20:47 编辑
王震宇 发表于 2011-8-20 10:09 
所以：干扰素有后劲和干扰素不耐药，都是屁话！
结论还为时过早.
http://www.hivandhepatitis.com/2009icr/aasld/docs/111709_c.html
Extended Therapy
In a related study, X.P. Chen from China assessed the potential benefits of extending pegylated interferon therapy to 72 weeks in chronic hepatitis B patients who did not respond after 48 weeks of treatment.
In this open-label study, 67 HBeAg positive patients with normal or mildly elevated ALT were randomly assigned to receive either 180 mcg/week pegylated interferon alfa-2a for 48 weeks or the oral antiviral drug entecavir (Baraclude) at 0.5 mg/day for 72 weeks.
A total of 12 patients in the pegylated interferon arm who did not achieve HBeAg seroconversion, HBV DNA < 1000copies/mL, or HBsAg < 1500 IU/mL by week 48 continued on the same regimen for a further 24 weeks (for a total of 72 weeks).
Results
 | At week 72, 44% of patients in the pegylated interferon arm achieved HBeAg seroconversion, compared with 18% in the entecavir arm. | | 15% and 3%, respectively, experienced HBsAg clearance. | | 72 week HBeAg seroconversion response rates were higher among pegylated interferon recipients with elevated baseline ALT compared than among those with normal ALT (52% vs 23%, respectively). | | High rates of HBeAg seroconversion were observed in patientswith HBsAg < 1500 IU/mL at weeks 12 and 24 (75% and 67%, respectively). |
"Pegasys was superior to entecavir in achieving HBeAg seroconversion and HBsAg clearance at week 72," the investigators concluded. "Patients without a response to pegylated interferon at week 48 achieved HBeAg seroconversion and HBsAg clearance when therapy was extended."
Guangdong Academy of Medical Science, Guangdong General Hospital, Guangzhou, China.
11/17/09
扩展治疗
在一项相关研究，来自中国的X.P
陈评估延长聚乙二醇干扰素治疗的潜在益处，至72周的慢性乙型肝炎患者，治疗48周后没有回应。
在这个开放标签的研究中，67 e抗原阳性的患者与正常或轻度升高的ALT被随机分配接受为180微克/周聚乙二醇干扰素α- 2a的48周或口服抗病毒药物恩替卡韦（博路定）在0.5毫克/天72周。
一个12例患者总在聚乙二醇干扰素的胳膊，谁没有实现HBeAg血清转换，HBV DNA <1000拷贝/毫升，或HBsAg<1500 IU/ mL的48周继续在同一疗程为24周（共72周）。
结果
在72周时，44％的患者在聚乙二醇干扰素臂实现HBeAg血清学转换，在恩替卡韦组18％相比。
分别为15％和3％，经验丰富的HBsAg清除。
72周的HBeAg血清转换的响应率较高，与基线ALT升高高于ALT正常（分别为52％比23％）相比，聚乙二醇干扰素者之间。
高HBeAg血清转换率，观察患者与HBsAg<1500 IU/ mL的12和24周（分别为75％和67％）。
“派罗欣优于恩替卡韦在实现HBeAg血清转换和HBsAg清除72周，研究人员得出结论。” “没有聚乙二醇干扰素治疗48周时的反应的患者达到HBeAg血清转换和HBsAg清除延长治疗时。”
广东省医学科学院，广东省人民医院，广州，中国。
09年11月17日
|
|
楼主: 王震宇
发表于 2011-8-20 10:08
